X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (516) 516
humans (370) 370
glycoside hydrolase inhibitors (264) 264
male (197) 197
animals (164) 164
diabetes mellitus, type 2 - drug therapy (163) 163
female (158) 158
hypoglycemic agents - therapeutic use (145) 145
middle aged (114) 114
acarbose (112) 112
hypoglycemic agents - adverse effects (93) 93
glycoside hydrolase inhibitors - pharmacology (92) 92
endocrinology & metabolism (88) 88
adult (85) 85
diabetes (85) 85
aged (84) 84
pharmacology & pharmacy (83) 83
alpha-glucosidases - metabolism (80) 80
enzyme inhibitors - therapeutic use (77) 77
biochemistry & molecular biology (74) 74
hypoglycemic agents - pharmacology (74) 74
blood glucose - metabolism (72) 72
alpha-glucosidase (70) 70
rats (70) 70
1-deoxynojirimycin - analogs & derivatives (67) 67
mice (63) 63
enzymes (62) 62
type 2 diabetes (61) 61
hypoglycemic agents - administration & dosage (59) 59
diabetes mellitus (57) 57
enzyme inhibitors - pharmacology (57) 57
enzyme inhibitors - adverse effects (56) 56
glycoside hydrolase inhibitors - therapeutic use (55) 55
α-glucosidase (54) 54
diabetes mellitus, type 2 - blood (53) 53
glycoside hydrolase inhibitors - chemistry (53) 53
glucose (51) 51
plant extracts - pharmacology (51) 51
chemistry, medicinal (50) 50
analysis (49) 49
insulin (48) 48
sulfonylurea compounds - therapeutic use (48) 48
acarbose - therapeutic use (47) 47
dose-response relationship, drug (47) 47
alpha-glucosidase inhibitor (46) 46
hyperglycemia (45) 45
treatment outcome (45) 45
administration, oral (43) 43
alpha-amylases - antagonists & inhibitors (43) 43
insulin - blood (43) 43
plant extracts - chemistry (43) 43
blood glucose - drug effects (42) 42
drug therapy, combination (40) 40
food science & technology (40) 40
glucosidase (40) 40
time factors (39) 39
blood glucose - analysis (38) 38
metformin - therapeutic use (38) 38
research (35) 35
thiazolidinediones - therapeutic use (35) 35
antioxidants (34) 34
chemistry, applied (34) 34
double-blind method (34) 34
glycoside hydrolases - metabolism (34) 34
inositol - analogs & derivatives (34) 34
insulin - therapeutic use (34) 34
plant sciences (34) 34
metformin (33) 33
amylase (32) 32
medicine, general & internal (32) 32
alpha-glucosidase inhibitors (31) 31
diabetes mellitus - drug therapy (31) 31
glycemic control (31) 31
abridged index medicus (30) 30
acarbose - adverse effects (30) 30
care and treatment (30) 30
enzyme inhibitors - administration & dosage (30) 30
enzyme inhibitors - chemistry (30) 30
glycoside hydrolase inhibitors - adverse effects (30) 30
hypoglycemic agents - chemistry (30) 30
molecular structure (30) 30
trisaccharides - adverse effects (30) 30
efficacy (29) 29
glycated hemoglobin a - analysis (29) 29
glycated hemoglobin a - metabolism (29) 29
mellitus (29) 29
structure-activity relationship (29) 29
trisaccharides - therapeutic use (29) 29
glucosamine - analogs & derivatives (28) 28
nutrition & dietetics (28) 28
α-glucosidase inhibitor (28) 28
hyperglycemia - drug therapy (27) 27
imino pyranoses (27) 27
in-vitro (26) 26
inhibitors (26) 26
kinetics (26) 26
sulfonylurea compounds - adverse effects (26) 26
dipeptidyl-peptidase iv inhibitors - therapeutic use (25) 25
inhibition (25) 25
randomized controlled trials as topic (25) 25
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (531) 531
Japanese (15) 15
German (8) 8
Chinese (1) 1
Czech (1) 1
French (1) 1
Italian (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Medicinal Chemistry, ISSN 0223-5234, 03/2015, Volume 93, pp. 564 - 573
A series of novel chalcone-triazole derivatives were synthesized and screened for in vitro anticancer activity on the human cancer cell lines IMR32... 
1,2,3-Triazoles | α-Glucosidase inhibition | Chromanochalcones | Molecular docking | Anticancer activity | CHEMISTRY, MEDICINAL | CLICK CHEMISTRY | ALPHA-GLUCOSIDASE | DRUG DISCOVERY | BIOLOGICAL EVALUATION | alpha-Glucosidase inhibition | HIV-1 PROTEASE | INHIBITORS | CANCER-RESEARCH | DERIVATIVES | ANTIMICROBIAL ACTIVITY | Triazoles - adverse effects | Chalcone - chemistry | Glycoside Hydrolase Inhibitors - adverse effects | Hypoglycemic Agents - metabolism | Antineoplastic Agents - chemical synthesis | Glycoside Hydrolase Inhibitors - metabolism | Humans | Structure-Activity Relationship | Antigens, Neoplasm - chemistry | Antineoplastic Agents - metabolism | DNA-Binding Proteins - metabolism | Tissue Distribution | Antineoplastic Agents - adverse effects | DNA Topoisomerases, Type II - chemistry | Antigens, Neoplasm - metabolism | Triazoles - chemical synthesis | Antineoplastic Agents - pharmacology | DNA Topoisomerases, Type II - metabolism | Chemistry Techniques, Synthetic | Rats | Glycoside Hydrolase Inhibitors - pharmacology | DNA-Binding Proteins - chemistry | Hypoglycemic Agents - pharmacology | Glycoside Hydrolase Inhibitors - chemical synthesis | Triazoles - pharmacology | Triazoles - metabolism | Animals | Hypoglycemic Agents - chemical synthesis | Cell Line, Tumor | Protein Conformation | Cell Proliferation - drug effects | Molecular Docking Simulation | Hypoglycemic Agents - adverse effects | alpha-Glucosidases - metabolism | Anthracyclines | Research | Diabetes | Triazoles | Oncology, Experimental | Cancer | Index Medicus
Journal Article
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 08/2014, Volume 16, Issue 8, pp. 761 - 765
We assessed the efficacy and safety of sitagliptin compared with α‐glucosidase inhibitor ( αGI ) in 120 of Japanese patients with type 2 diabetes mellitus (... 
type 2 diabetes | DPP‐IV | inhibitor | sulphonylureas | α‐glucosidase inhibitor | randomized trial | Type 2 diabetes | Randomized trial | α-glucosidase inhibitor | Sulphonylureas | DPP-IV inhibitor | VOGLIBOSE | MONOTHERAPY | HYPERGLYCEMIA | DOUBLE-BLIND TRIAL | alpha-glucosidase inhibitor | ENDOCRINOLOGY & METABOLISM | MELLITUS | Glycated Hemoglobin A - analysis | Triazoles - adverse effects | Glycoside Hydrolase Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Pyrazines - therapeutic use | Hypoglycemia - prevention & control | 1-Deoxynojirimycin - therapeutic use | Drug Therapy, Combination - adverse effects | Inositol - therapeutic use | Inositol - adverse effects | 1-Deoxynojirimycin - analogs & derivatives | Female | 1-Deoxynojirimycin - adverse effects | Sitagliptin Phosphate | Hypoglycemia - chemically induced | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Japan | Sulfonylurea Compounds - therapeutic use | Inositol - analogs & derivatives | Diabetes Mellitus, Type 2 - blood | Gastrointestinal Agents - therapeutic use | Pyrazines - adverse effects | Aged | Gastrointestinal Agents - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | alpha-Glucosidases - metabolism | alpha-Glucosidases - chemistry | Index Medicus
Journal Article
Blood Cells, Molecules and Diseases, ISSN 1079-9796, 02/2018, Volume 68, pp. 173 - 179
Journal Article
Cardiovascular Diabetology, ISSN 1475-2840, 01/2018, Volume 17, Issue 1, pp. 20 - 20
Journal Article
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2015, Volume 10, Issue 5, pp. e0125421 - e0125421
Journal Article
Journal Article
Diabetes & Vascular Disease Research, ISSN 1479-1641, 1/2016, Volume 13, Issue 1, pp. 2 - 12
Aims: With the intensification of antidiabetic treatment, there is an increasing risk of hypoglycaemia. We aimed to determine incidence, characteristics and... 
predictors | adverse effects | comorbidity | glucose variability | Hypoglycaemia | GLUCOSE CONTROL | HEART-FAILURE | FOLLOW-UP | RISK | IMPAIRED AWARENESS | VASCULAR-DISEASE | INSULIN | GLYCEMIC VARIABILITY | FREQUENCY | ENDOCRINOLOGY & METABOLISM | PERIPHERAL VASCULAR DISEASE | ANTIDIABETIC PHARMACOTHERAPY | Hypoglycemia - epidemiology | Metformin - therapeutic use | Prospective Studies | Glycoside Hydrolase Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Glycoside Hydrolase Inhibitors - therapeutic use | Male | Asymptomatic Diseases | Diabetes Mellitus, Type 2 - metabolism | Metformin - adverse effects | Incidence | Patient Care Planning | Thiazolidinediones - therapeutic use | Amputation | Female | Depressive Disorder - epidemiology | Hypoglycemia - chemically induced | Odds Ratio | Heart Failure - epidemiology | Risk Factors | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Diabetic Retinopathy - epidemiology | Angina, Stable - epidemiology | Diabetic Neuropathies - epidemiology | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Insulin - therapeutic use | Index Medicus
Journal Article
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 02/2015, Volume 31, Issue 2, pp. 155 - 167
Journal Article